{"id":"ionis-ghr-lrx","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Platelet reduction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"The drug uses antisense technology to target and reduce messenger RNA encoding the growth hormone receptor, thereby decreasing GHR protein levels and attenuating growth hormone-mediated signaling pathways. This approach is intended to modulate pathways associated with acromegaly and other growth hormone-related disorders.","oneSentence":"IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:56:08.895Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"}]},"trialDetails":[{"nctId":"NCT04522180","phase":"PHASE2","title":"A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2021-01-04","conditions":"Acromegaly","enrollment":34},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT03548415","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2018-09-13","conditions":"Acromegaly","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IONIS GHR-LRx","genericName":"IONIS GHR-LRx","companyName":"Ionis Pharmaceuticals, Inc.","companyId":"ionis-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IONIS GHR-LRx is an antisense oligonucleotide that inhibits growth hormone receptor (GHR) expression to reduce growth hormone signaling. Used for Acromegaly.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}